ebook Munafa Stock Market Course + Intraday & FNO calls  

       

524816 announcements Natco Pharm announcements and dividends declared BSE

Natco Pharm Complete list of announcements declared & dividend announcements by Natco Pharm 524816

Natco Pharm 524816 listed on BSE and deals in

Announcements and dividends declared by Natco Pharm 524816

Natco Pharma Q4 results: Net profit dips 43% to Rs 53 crore
Total income during the fourth quarter stood at Rs 360 crore, down from Rs 477 crore in the fourth quarter of the financial year 2019-20, the drugmaker said in a regulatory filing.
Announcement as on 17 June 2021

Natco Pharma's marketing partner gets USFDA nod for anti-cancer drug
Natco Pharma said based on the ANDA filing date, the company believes that it is eligible for 180 days of sole generic marketing exclusivity for the 10 mg strength and shared 180 days of generic marketing exclusivity for the 60 mg strength of the product a
Announcement as on 14 June 2021

Natco Pharma surges 20%, hits new high on USFDA nod for cancer drug
The company has received approval from the US health regulator for the generic version of Celgene's multiple myeloma drug, Revlimid (Lenalidomide) capsules in the US
Announcement as on 24 May 2021

Natco Pharma gets American drug regulator's nod for generic cancer treatment drug
Natco, along with its marketing partner Arrow International previously settled the Paragraph IV litigation related to the product with Celgene, now part of Bristol-Myers Squibb, who sells the product under the brand name 'Revlimid', it added.
Announcement as on 22 May 2021

Eli Lilly inks pact with Natco Pharma for Covid-19 drug baricitinib
Drug firm Eli Lilly said it has signed a voluntary licensing agreement with Natco Pharma to further expedite the availability of baricitinib for Covid-19 patients in India
Announcement as on 17 May 2021

Announcements by Natco Pharm first page | Next page | Prev page |

524816 Natco Pharm current price & indicator signals

Moving Averages for Natco Pharm

  • 5Day Average: 879.44
  • 12Day Average: 897.73
  • 20Day Average: 907.61
  • 50Day Average: 919.52
  • 100Day Average: 995.16
  • 150Day Average: 964.42
  • 200Day Average: 943.58

524816 Indicators & signals

Indicator MACD (12,26,9)

893.52, 909.39, -12.39
Indicator MACD is in negative zone

Indicator ADX (14)

3.3, 18.21, 19.45
Indicator ADX is indicating that momentum is weak.
Momentum is towards selling.

Indicator RSI (14)

Current RSI is: 45
Indicator RSI is indicating buying momentum and stock might rise.

Recent prices of 524816 Natco Pharm are as follows: Daily volume is divided by 10 day averaged volume

Date Close Range Change % Volume
25 Tue Aug 2026 866.45 865.25 to 889.95 -1.92% 0.49 times
24 Mon Aug 2026 883.45 876.90 to 892.40 0.11% 0.8 times
21 Fri Aug 2026 882.50 877.95 to 900.00 0.54% 0.69 times
20 Thu Aug 2026 877.75 875.30 to 894.30 -1.05% 0.64 times
19 Wed Aug 2026 887.05 883.10 to 916.60 -1.2% 0.27 times
18 Tue Aug 2026 897.80 889.70 to 900.10 0.91% 0.34 times
17 Mon Aug 2026 889.70 870.70 to 898.85 -1.41% 1.12 times
14 Fri Aug 2026 902.40 885.75 to 962.25 -5.23% 3.45 times
13 Thu Aug 2026 952.25 917.60 to 960.40 4.07% 1.53 times
12 Wed Aug 2026 915.00 906.00 to 922.00 0.89% 0.45 times
11 Tue Aug 2026 906.90 903.55 to 929.40 -0.5% 0.72 times
10 Mon Aug 2026 911.50 905.55 to 932.00 -0.62% 0.68 times

Videos related to: 524816 announcements Natco Pharm announcements and dividends declared BSE

Hindi Video Correct Way Of Fundamental Analysis Using EPS And PE - MunafaSutra

Hindi Video What Is Needed To Succeed In Stock Markets

524816 announcements Natco Pharm announcements and dividends declared BSE

 

Back to top